A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use o...

Descripción completa

Detalles Bibliográficos
Autores principales: Drenberg, Christina D., Shelat, Anang, Dang, Jinjun, Cotton, Anitria, Orwick, Shelley J., Li, Mengyu, Jeon, Jae Yoon, Fu, Qiang, Buelow, Daelynn R., Pioso, Marissa, Hu, Shuiying, Inaba, Hiroto, Ribeiro, Raul C., Rubnitz, Jeffrey E., Gruber, Tanja A., Guy, R. Kiplin, Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522510/
https://www.ncbi.nlm.nih.gov/pubmed/31097698
http://dx.doi.org/10.1038/s41467-019-09917-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522510/
https://www.ncbi.nlm.nih.gov/pubmed/31097698
http://dx.doi.org/10.1038/s41467-019-09917-0

Ejemplares similares